Amended Statement of Ownership (sc 13g/a)
September 09 2019 - 3:09PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Act of 1934
(Amendment No. 1)
ENLIVEX
THERAPEUTICS LTD.
(Name of Issuer)
Ordinary Shares, par value NIS 0.40 per
share
(Title of Class of Securities)
M4130Y106
(CUSIP Number)
September 1, 2019
(Date of event which requires filing of
this statement)
Check the appropriate
box to designate the rule pursuant to which this Schedule is filed:
*The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page.
The information required
on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange
Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
CUSIP No. M4130Y106
1
|
NAME OF REPORTING PERSON
Michael Hobi
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A
GROUP
(a) ☐
(b) ☐
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5
|
SOLE VOTING POWER
|
498,432
|
6
|
SHARED VOTING POWER
|
0
|
7
|
SOLE DISPOSITIVE POWER
|
498,432
|
8
|
SHARED DISPOSITIVE POWER
|
0
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
498,432
|
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES
|
☐
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN
ROW 9
4.93%(1)
|
|
12
|
TYPE OF REPORTING PERSON
IN
|
|
|
(1)
|
Based on 10,113,707 ordinary shares issued and outstanding as of June 5, 2019.
|
CUSIP No. M4130Y106
|
Item 1(a)
|
Name of Issuer:
|
Enlivex Therapeutics
Ltd. (the “Issuer”)
|
Item 1(b)
|
Address of Issuer’s Principal Executive Offices:
|
14 Einstein Street,
Nes Ziona, Israel 7403618.
|
Item 2(a)
|
Name of Person Filing:
|
Michael Hobi
|
Item 2(b)
|
Address or Principal Business Office or, if none, Residence:
|
Färberstrasse
4
CH-8832 Wollerau
Switzerland
Switzerland
|
Item 2(d)
|
Title of Class of Securities:
|
Ordinary shares, NIS
0.40 per share
M4130Y106
|
Item 3
|
If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person
filing is a:
|
Not applicable.
Reporting Person
|
|
Number of Outstanding Ordinary Shares Beneficially Owned
|
|
|
Percentage of Outstanding Ordinary Shares (1)
|
|
|
|
|
|
|
|
|
|
|
Michael Hobi (2)
|
|
|
498,432
|
|
|
|
4.93
|
%
|
|
(1)
|
Percentage based upon 10,113,707 ordinary shares issued
and outstanding as of June 5, 2019.
|
|
(2)
|
Michael Hobi has sole voting and dispositive power over
all reported shares.
|
CUSIP No. M4130Y106
|
Item 5
|
Ownership of Five Percent or Less of a Class.
|
If this statement is
being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than
5 percent of the class of securities, check the following ☒
|
Item 6
|
Ownership of More than Five Percent on Behalf of Another Person.
|
Not applicable.
|
Item 7
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported
on by the Parent Holding Company or Control Person.
|
Not applicable.
|
Item 8
|
Identification and Classification of Members of the Group.
|
Not applicable.
|
Item 9
|
Notice of Dissolution of Group.
|
Not applicable.
Not applicable.
CUSIP No. M4130Y106
SIGNATURES
By signing below I
certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely
in connection with a nomination under §240.14a-11.
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: September 9, 2019
|
Michael Hobi
|
|
|
|
/s/ Michael Hobi
|
5
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Apr 2024 to May 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From May 2023 to May 2024